Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANO3 antisense RNA 1 (ANO3-AS1) is an endogenous long non-coding RNA transcribed from the antisense strand of the ANO3 gene locus on the human genome[1][3]. As a natural antisense transcript (NAT), its primary presumed function—based on antisense RNA biology—is to regulate the expression, stability, or processing of the sense *ANO3* mRNA through cis- or trans-acting mechanisms[3][5][6]. Antisense RNAs can modulate gene expression via DNA methylation, histone modifications, or by directly interacting with their complementary mRNAs, sometimes affecting mRNA stability or translation[3][6][7]. However, the specific biological function, disease association, or clinical relevance of ANO3-AS1 has not been described in detail in current scientific literature or major gene databases[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ANO3 antisense RNA 1 (ANO3-AS1).